Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches
Cancer Biomarkers · 2026-05 · 43
DOI: 10.1177/18758592261454886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, online erschienen am 28.05.2026. Verfasst von Faeze Shahraki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Computational Biology, Biomarkers, Tumor. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ferdowsi University of Mashhad.
Abstract (Originalsprache)
Background
Integrated bioinformatics approaches were used to identify stage-specific candidate genes and potential drug targets in triple-negative breast cancer (TNBC).
Methods
Microarray (164 early-stage, 33 advanced-stage, and 53 normal samples) and RNA-seq (113 normal, 163 early-stage, and 30 advanced-stage TNBC samples) datasets were analyzed. Differentially expressed genes (DEGs) were identified, followed by co-expression analysis using Weighted Gene Co-expression Network Analysis (WGCNA) and protein–protein interaction analysis using the STRING database. miRNA co-regulation was evaluated using multiMiR and TCGA correlation analyses. Candidate genes were validated using UALCAN and immunohistochemistry data. Molecular docking assessed potential therapeutic agents.
Results
Novel stage-specific candidate biomarkers were identified, including DNAJC6 , SKP2 , MOCOS , and NCAPD2 in early-stage TNBC, and F11R , FOXO6 , PPP4C , and TMEM51 in advanced-stage TNBC. UALCAN analysis confirmed the dysregulation of these genes across 23 additional malignancies. STRING-based network analysis revealed stage-specific protein–protein interactions, including SKP2–SKP1 in early-stage and F11R–TJP1 in advanced-stage TNBC. miRNA co-regulation distinguished early-stage TNBC through PI3K–AKT–related pathways and advanced-stage TNBC through tumor progression–associated pathways. Docking-based drug repurposing highlighted conventional agents (e.g., doxorubicin) and potential novel candidates (e.g., sunitinib).
Conclusion
This study identifies novel stage-specific gene candidates and suggests repurposable drugs for TNBC, supporting progression-specific targeted therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran.
- Department of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Azadeh Meshkini
Förderung
- Ferdowsi University of Mashhad
Zitieren
APA
Shahraki, F., Meshkini, A., & Nazari, E. (2026). Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches. Cancer Biomarkers, 43. https://doi.org/10.1177/18758592261454886
Vancouver
Shahraki F, Meshkini A, Nazari E. Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches. Cancer Biomarkers. 2026;43. doi:10.1177/18758592261454886
BibTeX
@article{Shahraki2026,
author = {Shahraki, Faeze and Meshkini, Azadeh and Nazari, Elham},
title = {Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches},
journal = {Cancer Biomarkers},
year = {2026},
volume = {43},
doi = {10.1177/18758592261454886}
}
EUVIMED